CA2622975C - Adenosine a3 receptor agonists for the treatment of dry eye disorders - Google Patents

Adenosine a3 receptor agonists for the treatment of dry eye disorders Download PDF

Info

Publication number
CA2622975C
CA2622975C CA2622975A CA2622975A CA2622975C CA 2622975 C CA2622975 C CA 2622975C CA 2622975 A CA2622975 A CA 2622975A CA 2622975 A CA2622975 A CA 2622975A CA 2622975 C CA2622975 C CA 2622975C
Authority
CA
Canada
Prior art keywords
dry eye
a3ar
agonist
adenosine
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2622975A
Other languages
English (en)
French (fr)
Other versions
CA2622975A1 (en
Inventor
Pnina Fishman
Tatiana Reitblat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of CA2622975A1 publication Critical patent/CA2622975A1/en
Application granted granted Critical
Publication of CA2622975C publication Critical patent/CA2622975C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA2622975A 2006-01-27 2006-02-01 Adenosine a3 receptor agonists for the treatment of dry eye disorders Expired - Fee Related CA2622975C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76250606P 2006-01-27 2006-01-27
US60/762,506 2006-01-27
PCT/IL2006/000130 WO2007086044A1 (en) 2006-01-27 2006-02-01 Adenosine a3 receptor agonists for the treatment of dry eye disorders

Publications (2)

Publication Number Publication Date
CA2622975A1 CA2622975A1 (en) 2007-08-02
CA2622975C true CA2622975C (en) 2011-05-03

Family

ID=36794417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2622975A Expired - Fee Related CA2622975C (en) 2006-01-27 2006-02-01 Adenosine a3 receptor agonists for the treatment of dry eye disorders

Country Status (9)

Country Link
EP (1) EP1976494A1 (pt)
JP (2) JP5185139B2 (pt)
KR (1) KR101037095B1 (pt)
CN (1) CN101365430B (pt)
AU (1) AU2006336834B2 (pt)
BR (1) BRPI0621052A2 (pt)
CA (1) CA2622975C (pt)
IL (1) IL191271A (pt)
WO (1) WO2007086044A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
IL184620A0 (en) * 2007-07-15 2008-01-20 Can Fite Biopharma Ltd Composition for the treatment of inflammation
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
CA2732320C (en) 2008-08-01 2017-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
MX2011012229A (es) * 2009-05-17 2011-12-08 Can Fite Biopharma Ltd Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1549141A4 (en) * 2002-09-27 2008-06-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN
JPWO2005121320A1 (ja) * 2004-06-10 2008-04-10 協和醗酵工業株式会社 幹細胞自己複製促進剤
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren

Also Published As

Publication number Publication date
AU2006336834B2 (en) 2009-12-10
JP2013032396A (ja) 2013-02-14
IL191271A (en) 2014-03-31
KR101037095B1 (ko) 2011-05-26
JP5185139B2 (ja) 2013-04-17
CN101365430A (zh) 2009-02-11
CA2622975A1 (en) 2007-08-02
WO2007086044A1 (en) 2007-08-02
IL191271A0 (en) 2009-08-03
CN101365430B (zh) 2011-09-21
KR20080090517A (ko) 2008-10-08
EP1976494A1 (en) 2008-10-08
AU2006336834A1 (en) 2007-08-02
BRPI0621052A2 (pt) 2012-07-17
JP2009524647A (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
US20100222369A1 (en) Treatment for dry eye conditions
EP2614838B1 (en) Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye
JP2013032396A (ja) ドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
EP1778239B1 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
KR20080071609A (ko) 골관절염 치료를 위한 ａ3 아데노신 수용체 아고니스트의용도
AU2010250759B2 (en) A3 adenosine receptor agonists for the reduction of intraocular pressure
MX2008009506A (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
US20130045943A1 (en) A3ar agonists for the treatment of uveitis
HK1166264A (en) A3 adenosine receptor agonists for the reduction of intraocular pressure
Singh Review of various lacrimomimetics: making the appropriate choice
Lee et al. Lodoxamide in vernal keratoconjunctivitis
HK1184686B (en) Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160201